MAIA Labs wins EU CE clearance for AI colonoscopy assistant

MAIA Labs has secured CE certification under the EU Medical Device Regulation for ColoMAIA II, clearing the AI colonoscopy assistant for commercial use across Europe. The company says a 600-patient multicenter trial showed a 61% relative increase in adenomas detected per colonoscopy, and the system is already deployed in more than 20 European hospitals. Why it matters: - ColoMAIA II is now cleared for commercial sale across Europe, putting an AI tool designed to help physicians find more precancerous colorectal lesions into routine clinical use. - Colorectal cancer is the second leading cause of cancer death in the United States and Europe. - Standard colonoscopy can miss adenomas, with published miss rates of about 20% to 27%. - Detecting and removing precancerous lesions early can prevent cancers that might develop three to five years later. What happened: - MAIA Labs received CE certification under the EU Medical Device Regulation for ColoMAIA II, its AI-powered colonoscopy assistant. - The certification is backed by a prospective multicenter clinical trial involving 600 patients. - The study showed a 61% relative increase in adenomas detected per colonoscopy compared with standard colonoscopy. - The system is already deployed in more than 20 European hospitals. The details: - ColoMAIA II acts as a second pair of eyes during colonoscopy. - The system detects adenomas in real time and assesses dozens of additional metrics during the procedure. - ColoMAIA II requires no changes to established clinical workflows for physicians or patients. - The system connects to standard endoscopy towers without hardware replacement. - It runs detection automatically during the procedure. - ColoMAIA II generates a structured quality report before the physician leaves the room. - The software eliminates more than one hour of manual documentation per day. - The system exports findings directly to hospital EMR and PACS systems. Between the lines: - European CE clearance is a major hurdle for medical AI products, and MAIA Labs is using it to position ColoMAIA II as a clinically validated workflow tool rather than a standalone gadget. - CEO Lukas Loun framed the certification as evidence of clinical maturity and said the company is focused on getting the technology to physicians and patients worldwide. - MAIA Labs says healthcare AI leadership depends on clinical data, physician trust and regulatory certification, all of which take years to build. - The company is working with the Czech innovation agency JIC as it pushes into new markets. - Ongoing collaborations with Mayo Clinic and Cleveland Clinic suggest MAIA Labs is trying to strengthen both evidence and credibility while it expands. What’s next: - MAIA Labs is accelerating commercial expansion and seeking distribution partners in new markets. - The company is pursuing FDA certification. - MAIA Labs says research and hospital collaborations will continue as it develops the platform further. The bottom line: - MAIA Labs now has a regulated AI product for colonoscopy, clinical trial data behind it and an installed base in Europe, giving the company a credible launchpad for wider global expansion. - The company website is More information - JIC’s social profile is JIC on LinkedIn